Table 2. Biometrics and EDP data of samples with unequivocal results stratified according to HIV status.
| Sample group | Bacteremic (BC positive) HIV positive | Bacteremic (BC positive) HIV negative | Non- bacteremic bacterial infection (BC negative, excluding TB), HIV positive | Non- bacteremic bacterial infection (BC negative, excluding TB), HIV neg | Bacterial infection negativeHIV pos | Bacterial infection negative HIV neg |
|---|---|---|---|---|---|---|
| Number of samples | 8 | 6 | 9 | 7 | 2 | 5 |
| Male: Female | 0.14:1 | 0.2:1 | 0.8:1 | 0.8:1 | 0:1 | 0.25:1 |
| Median Age [IQR] (years) | 36 (25.8–53.8) | 28 (13.4–29) | 35.5 (25.5–47.8) | 13 (2.4–37.3) | 24 (21–27) | 11 (1–47) |
| Median CD4 count [IQR] (cells/ul) | 93 (58–406 | Not applicable | 145 (42–172) | Not applicable | Too few results for calculation | Not applicable |
| nCD64:lCD64 | ||||||
| Median | 12.3 | 15.0 | 6.4 | 6.8 | 2.26 | 1.06 |
| IQR | 9.8–38.1 | 1.95–30.5 | 3.4–17.0 | 2.6–8.9 | 1.6–2.3 | 1–10.6 |
| p-value* | 0.003 | 0.048 (0.13ǂ) | 0.01 | 0.027 (0.27ǂ) | ||
| mCD64:lCD64 | ||||||
| Median | 40.8 | 45.4 | 45.1 | 47.2 | 41.8 | 43.1 |
| IQR | 36.5–59.4 | 10.3–95.5 | 13.1–85.6 | 22.8–56.5 | 33.8–49.8 | 18.6–66.2 |
| p-value* | 0.43 | 0.97 (0.93ǂ) | 0.95 | 0.69 (0.87ǂ) | ||
| nCD64:mHLA-DR | ||||||
| Median | 2.42 | 0.75 | 0.84 | 0.54 | 0.33 | 0.07 |
| IQR | 0.92–9.1 | 0.61–1.2 | 0.2–3.1 | 0.13–0.82 | 0.04–0.62 | 0.02–0.43 |
| p-value* | 0.0003 | 0.0018 (0.017ǂ) | 0.008 | 0.068 (0.149ǂ) | ||
| NE-WY | ||||||
| Median | 806 | 837 | 793 | 755 | 655.0 | 788 |
| IQR | 710.8–943.3 | 766.5–1047.0 | 926–1384 | 660–893 | 617–693 | 702.5–846 |
| p-value* | 0.10 | 0.032 (0.25ǂ) | 0.44 | 0.5 (0.93ǂ) | ||
| NE-SFL | ||||||
| Median | 59.0 | 55.0 | 52.5 | 53.0 | 47.4 | 46.5 |
| IQR | 56.0–74.7 | 46.3–60.9 | 47.4–54.6 | 45.2–54.9 | 46.2–48.6 | 43.2–52.7 |
| p-value* | 0.0016 | 0.12 (0.33ǂ) | 0.028 | 0.096 (0.33ǂ) | ||
| MO-Y | ||||||
| Median | 106.1 | 107.2 | 104.4 | 100.9 | 115.8 | 103.8 |
| IQR | 95.5–116.3 | 94.8–115.1 | 101.6–119.3 | 95.3–107.3 | (115.8–115.8) | 93.6–108.4 |
| p-value* | 0.64 | 0.63 (0.54ǂ) | 0.37 | 0.61 (1.0ǂ) | ||
| Automated IG count | ||||||
| Median | 2.1 | 2.4 | 1.4 | 1.1 | 0.75 | 0.5 |
| IQR | 0.7–2.8 | 1.3–5.1 | 1.1–6.9 | 0.6–3.1 | 0.7–0.8 | 0.5–1.7 |
| p-value* | 0.07 | 0.0065 (0.035ǂ) | 0.025 | 0.13 (0.34ǂ) | ||
| Abs auto IG (x10 9 /L) | ||||||
| Median | 0.14 | 0.29 | 0.16 | 0.19 | 0.09 | 0.04 |
| IQR | 0.04–0.38 | 0.13–0.8 | 0.1–0.86 | 0.06–0.45 | 0.05–0.12 | 0.03–0.25 |
| p-value* | 0.20 | 0.0085 (0.052ǂ) | 0.032 | 0.032 (0.06ǂ) |
*The p-values are derived from comparison with the infection negative cases.
ǂ P-vales were derived from comparison to the bacterial infection negative group without HIV. Unfortunately, the number of bacterial infection negative cases in people with HIV was too small to allow for this comparison in the patients with HIV.
nCD64:lCD64, neutrophil CD64:lymphocyte CD64; mCD64:lCD64, monocyte CD64:lymphocyte CD64
nCD64:mHLA-DR, neutrophil CD64:monocyte HLA-DR; NE-WY, fluorescent light distribution width of the neutrophil area; NE-SFL, fluorescent light intensity of the neutrophil area; IG%, immature granulocyte percentage; CRP, C-reactive protein; Pct, procalcitonin; Abs auto IG, absolute automated IG count.